Industry Adoption of Organoids and Organs‐on‐Chip Technology: Toward a Paradox of Choice

Abstract

During the last decade, organoid and organs‐on‐chip technologies have significantly enhanced the ability to model human biology in vitro. For the pharmaceutical industry, this represents an opportunity to augment, or possibly replace, traditional preclinical animal studies with more clinically predictive tools. In the last few years, the marketplace for new human model systems has expanded rapidly. While pharma companies welcome the breadth of new options, ample choice can be paralyzing. Even for experts from the model developer community who are now filling the ranks in the industry, the pairing of the right model for a specific, fit‐for‐purpose biological question can be daunting. As a community, the adoption of these models can be hastened in the industry by publishing high dimensional datasets (e.g., multiomic, imaging, functional, etc.) on existing model systems, termed model‐omics, and storing them in publicly accessible databases. This action will allow for quick cross‐model comparisons and provide a sought‐after rationale for either routine or fit‐for‐purpose use of organoids or organs‐on‐chip during drug development.

Research progress of biomaterials and innovative technologies in urinary tissue engineering

“…Organoids also enables us to carry out further complex research by successfully simulating the tissue architecture and cellular disposition of normal bladder in vivo . In addition, organ-on-a-chip platforms combining organoids and microfluidic systems will help to establish more complex experimental models of multiple organ systems, and conduct efficient and economical toxicity tests, drug discovery, and drug screening ( Berlo et al, 2021 ; Homan, 2023 ; Zhu et al, 2023 ).…”

“…In addition, organ-on-a-chip platforms combining organoids and microfluidic systems will help to establish more complex experimental models of multiple organ systems, and conduct efficient and economical toxicity tests, drug discovery, and drug screening (Berlo et al, 2021;Homan, 2023;Zhu et al, 2023).…”